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ABSTRACT  
Erythro-myeloid progenitors (EMPs) were recently described to arise from the yolk sac 
endothelium, just prior to vascular remodeling, and are the source of adult/post-natal tissue 
resident macrophages. Questions remain, however, concerning whether EMPs differentiate 
directly from the endothelium or merely pass through. We provide the first evidence in vivo that 
EMPs can emerge directly from endothelial cells (ECs) and demonstrate a role for these cells in 
vascular development. We find that EMPs express most EC markers but late EMPs and EMP-
derived cells do not take up acetylated low-density lipoprotein (AcLDL), as ECs do. When the 
endothelium is labelled with AcLDL before EMPs differentiate, EMPs and EMP-derived cells 
arise that are AcLDL+. If AcLDL is injected after the onset of EMP differentiation, however, the 
majority of EMP-derived cells are not double labelled. We find that cell division precedes entry 
of EMPs into circulation, and that blood flow facilitates the transition of EMPs from the 
endothelium into circulation in a nitric oxide-dependent manner. In gain-of-function studies, we 
inject the CSF1-Fc ligand in embryos and found that this increases the number of CSF1R+ cells, 
which localize to the venous plexus and significantly disrupt venous remodeling. This is the first 
study to definitively establish that EMPs arise from the endothelium in vivo and show a role for 
early myeloid cells in vascular development. 
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INTRODUCTION  
The first myeloid cells develop in the mouse embryo during yolk sac hematopoiesis from 
primitive macrophage-restricted progenitors at embryonic day 7.5 (E7.5) and from erythro-
myeloid progenitors (EMPs) at E8.5 1,2. Recent fate mapping reports show that EMPs are 
sufficient to support embryo survival until birth 3, and can develop into tissue resident 
macrophages that have self-renewing properties 2,4-7. While EMP can differentiate into 
macrophages within the yolk sac, they also colonize the fetal liver from E9 8 and differentiate 
into erythrocytes, megakaryocytes, macrophages, monocytes granulocytes and mast cells 2. 
Whether EMP-derived macrophages bypass the monocyte stage of differentiation is still 
controversial as very little is known about their differentiation pathway 7,9. Understanding EMP 
renewal and differentiation is important, since defects in EMP development could result in long-
term effects on tissue resident macrophages. 
In mouse embryos, endothelial cells of the aorta-gonad-mesonephros (AGM) region and 
vitelline arteries have been shown to produce hematopoietic stem cells (HSCs) 10-15. While 
surface marker analyses imply that EMPs also derive from endothelial cells 2,4,16,17, to date this 
has not been conclusively demonstrated. For instance, we were the first to identify that early 
EMPs arise from Tie2+ cells 2. Our findings were not intended to assert an endothelial cell origin 
of EMPs, because Tie2 is not endothelial-specific at this stage but is also expressed by 
mesodermal cells 18,19. Nevertheless, several groups subsequently showed that EMPs express a 
number of endothelial cell genes, including VE-Cadherin, PECAM-1, CD105 and CD34 17,20,21. 
Importantly, the expression of common markers between endothelial precursors and 
hematopoietic cells does not prove a common origin 22,23, particularly in the absence of in vivo 
validation. EMPs have also been observed in the vessel wall 20,21; however, it can be argued that 
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EMPs actually develop in the mesoderm near vessels and only transiently pass through the 
endothelium, as has been observed for HSCs in the AGM 24. As such, prior to this report, 
evidence that EMPs arise directly from endothelial cells was indirect and required substantiation.  
EMPs are first observed at E8.5 2, a stage when blood flow and vascular remodeling 
initiates. This raises the question as to whether blood flow is required for their development, and 
whether EMPs play a role in early vascular development. While the function of yolk sac EMPs 
in early vascular development is elusive, adult macrophages and myeloid cells are known to 
modulate vascular remodeling by promoting angiogenesis (sprouting of new vessels) and 
arteriogenesis (changes in vessel diameter in response to flow dynamics) 25-27. To date, the 
earliest vascular function attributed to yolk sac-derived macrophages is in mediating vessel 
anastomosis at E11.5 28,29, but these cells represent tissue differentiated cells and not EMPs per 
se. Csf1r-/- mice lack yolk sac-derived macrophages at E12.5 5, yet no pre-natal vascular 
abnormalities were reported in these mice 30. The absence of yolk sac derived macrophages was 
not verified prior to E12.5 and thus it is not clear if the mutation affected their initial 
differentiation or their long-term survival. More recent studies in Ncx-/- mouse embryos, which 
lack blood flow, found no difference in the number or morphology of EMPs at E10.0 20, 
suggesting that unlike for HSCs 31,32, EMP differentiation does not require hemodynamic forces.  
To address these points, we investigated the relationship of EMPs with the endothelium, 
blood flow, and vascular remodeling. Similar to recent findings 20, we found that EMPs reside in 
the blood vessels of the yolk sac at E8.5 and enter circulation over the following day. Further to 
this, we delineated the precise origins of EMPs. We found that the majority of EMPs develop 
from the blood islands, but that a third of circulating EMPs emerge from the capillary plexus and 
have an initial elongated and endothelial-like phenotype. At E9.0, EMPs are positive for most 
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endothelial cell markers, with the exception of acetylated low-density lipoprotein (AcLDL), 
which is taken up by endothelial cells but not EMPs. We therefore investigated earlier stages and 
find that AcLDL uptake is present in Runx1+ cells, but that this ability to uptake AcLDL is lost 
later. We then use AcLDL labelling combined with in vivo time-lapse imaging 33, to capture for 
the first time, EMP differentiation from the endothelium of developing mouse embryos. Contrary 
to previous reports, we found that blood flow facilitates the transition of EMPs into circulation 
through a nitric oxide-dependent mechanism. Using gain-of-function experiments, we show that 
EMPs in the yolk sac are required for normal remodeling of the venous plexus. This report 
identifies novel mechanisms and behavior of EMPs during embryonic vascular remodeling.  
 
RESULTS 
One third of EMPs arise from blood vessels outside of the blood islands 
To genetically label EMPs and EMP-derived cells during early vascular development, we used 
two transgenic myeloid-specific Cre recombinase mouse models: Csf1riCre (constitutive) and 
Csf1rMeriCreMer (tamoxifen-inducible). These mice were mated with Rosa26tdTomato mice to 
fluorescently label Csf1r-expressing cells and their progeny with tdTomato (tdT+). For the 
inducible iCre transgenic model, a single pulse of tamoxifen was administered to the dam at 
E7.75. We previously showed that this specifically labels EMPs 2, where 100% of labeled cells at 
E8.5 (11-13 somite pairs) are c-kit+, CD45low, AA4.1+. In agreement with previous reports 2,4-6, 
we found that yolk sac EMPs can contribute to tissue resident macrophages in neonate mouse 
tissues (Supplemental Fig. 1). It was previously reported that early EMPs express Csf1r mRNA 
but not CSF1R protein at E9.0 7.  We therefore also examined the expression of CSF1R protein 
in tdT+ cells. Though not all CSF1R+ cells expressed tdT at E8.5 (10 somite pairs), indicating 
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that Cre-mediated excision is not 100% penetrant, all tdT+ cells did express CSF1R protein 
(Supplemental Fig. 2). By E9.5 (25 somite pairs), some tdT+ cells no longer expressed CSF1R 
protein (Supplemental Fig. 2). The discrepancy with previous reports may simply be due to 
difference in the genetic backgrounds of the mouse strains.  
We then investigated the development of yolk sac EMPs using cell lineage tracing and 
immunofluorescence. As previously shown 2,34, EMPs are first detected at E8.5 (7-10 somite 
pairs, Fig. 1A), and the number of EMPs and EMP-derived cells increase by E9.0 (Fig. 1B) and 
further by E9.5 (Fig. 1C). The increase in EMP and EMP-derived cells was quantified by 
immunofluorescence on Csf1riCre Rosa26tdT embryos (Fig. 1D) and by flow cytometry of 
CSF1R+ cells in wild-type yolk sacs (Fig. 1E, Supplemental Fig. 3 for gating).  
Morphologically, both CSF1R+ wild-type cells and Csf1riCre Rosa26tdT labeled cells 
displayed two distinct phenotypes: the majority had a round or ovoid myeloid shape, while a 
subset adopted a flattened endothelial shape and were embedded within the blood vessel intima 
(Fig. 1F-H arrowheads). Blood vessels of the yolk sac were visualized with CD31 staining. We 
quantified the number of tdT+ cells with an endothelial phenotype based on three stringent 
criteria: CD31+ endothelial expression, flat and elongated morphology typical of endothelial 
cells, and integration in the vessel wall (Fig 1I). We found that at the onset of circulation at E8.5, 
32.8 ±8.0%% of tdT+ cells had an endothelial phenotype (Fig. 1I). Thereafter, the percentage of 
endothelial-like cells decreased to 11.6 ±4.5% at E9.0 and 6.8 ±3.8%% at E9.5. To investigate 
whether this coincided with loss of endothelial cell gene expression, we quantified the 
percentage of CSF1R+ cells that also stained positive for VE-Cadherin in wild type yolk sacs by 
flow cytometry (Fig. 1J). We found that at E8.5, 89.4 ±7.6%% of CSF1R+ cells are also positive 
for VE-Cadherin and that this was reduced to 60.8 ±10.3% at E9.5. Both analyses confirm a 
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decrease of endothelial characteristics for EMPs and EMP-derived cells with developmental 
stage; however, the results also indicate that CSF1R+ cells outside the endothelium continue to 
express endothelial cell markers. We further confirmed the endothelial association of EMPs 
using the endothelial reporter Cdh5(Pac) CreERT2 mouse 35. Dams were tamoxifen-induced when 
embryos were E7.5, yolk sacs were harvested at E9.0 and immuno-stained for CSF1R 
(Supplemental Fig. 4). We found that a high number of Cdh5-derived cells (Supplemental Fig. 4, 
red vessels) co-express CSF1R+ (Supplemental Fig. 4B and C, white arrowheads). However, not 
all CSF1R+ cells (green) were Cdh5-derived (red), which suggests that either only a subset of 
CSF1R+ cells arise from Cdh5-expressing endothelial cells or, alternatively, that Cre excision 
was not 100% penetrant. 
We observed a differential location of yolk sac EMPs and EMP-derived cells at E8.5 
based on phenotype: most of the rounded cells were located in the distal hematopoietic blood 
islands, whereas those with an endothelial morphology were located in regions of the yolk sac 
proximal to the embryo (Supplemental Fig. 5). We therefore cultured embryos with and without 
the blood islands to investigate the different sites of origin. Csf1riCreRosa26tdT embryos were 
harvested at E8.25 (3-5 somite pairs) prior to EMP development and the onset of flow. As a 
sham experiment, only the ectoplacental cone was removed, whereas in experimental embryos, 
both the ectoplacental cone and blood islands were removed (Fig. 2A). Embryos were cultured 
for 16 hours. At the end of culture, yolk sacs had healed and were inflated, even in embryos 
where the blood islands were removed (Fig. 2B). All embryos had viable heart beats. The 
morphology of the embryo proper was normal, but somewhat delayed in both sham and 
experimental groups such that neither set of embryos turned. We assessed the efficiency of blood 
island removal by quantifying erythroblasts by flow cytometry, and found a 96% reduction in 
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Ter119+ erythroblast post-operation. Specifically, an average of 5600 ±530 Ter119+ cells were 
present per sham-operated embryo (n=4), compared to 210 ±37 Ter119+ cells in blood-island 
removed embryos (n=5). Since a hemogenic endothelium is present at this stage, complete 
ablation of all erythroblasts would not occur even with removal of the blood islands.  We also 
observed that tdT+ cells developed in both control and experimental embryos (Fig. 2C), and 
quantified them by flow cytometry (Fig. 2D). We found that in control embryos, 5.0 ±0.8% of 
cells were tdT+, compared to only 1.6 ±0.6% in embryos cultured without blood islands. These 
culture experiments confirm that 32% of EMPs (i.e., 1.6% divided by 5.0%) develop in the yolk 
sac outside the blood islands, which corroborates our results obtained using endothelial cell 
morphology as criteria (Fig. 1I).  
 
EMPs only take up AcLDL while in the vessel wall  
We next sought to further characterize the presence of endothelial and hematopoietic markers in 
EMPs by immunostaining. 100% of CSF1R+ cells express c-kit at E9.0 (15 somite pairs) as we 
had previously found (Fig. 3A, white arrowheads) 2, and therefore represent EMPs at this stage. 
Previous reports have shown that EMPs continue to express CSF1R when they differentiate into 
myeloid cells but lose c-kit expression 2,17,20. All stainings were performed in littermates. A 
significant number of CSF1R+ cells also co-express the hematopoietic/endothelial marker CD34 
(Fig. 3B, white arrowheads). We found that CSF1R+ cells co-express VE-Cadherin and CD31 
(data not shown). Interestingly, we observe that the uptake of fluorescently-tagged AcLDL 
(AF488-AcLDL) labeled endothelial cells but never labeled CSF1R+ cells (Fig. 3C). CSF1R+ 
cells were rounded and located away from the vessel walls (Fig. 3C). 
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AcLDL uptake is mediated by scavenger receptors 36 and labels differentiated endothelial 
and macrophages in the adult. Primitive macrophages do not express scavenger receptors 37 and 
therefore would not be labeled by AcLDL. We further investigated whether AcLDL could 
differentially label endothelial cells, EMPs and/or EMP-derived cells. Csf1rMeriCreMer Rosa26tdT 
embryos were dissected at E8.0 (4-6 somite pairs) or E8.5 (10-12 somite pairs), injected intra-
vascularly with AF488-AcLDL, and placed in culture.  Hydroxy-tamoxifen was added directly to 
the culture media, and embryos were not exposed to tamoxifen in utero. This allowed precise 
timing of the onset of tdT expression. After 24 hours of culture, embryos were analyzed by flow 
cytometry. Remarkably, if the embryos were injected before the onset of EMP differentiation, 
the majority of tdT+ cells were also AcLDL labelled (Fig. 3D, 83.9% ±3.2, n=8).  However, if 
AcLDL was injected just 9 hours later (10-12 somite pairs), at a stage when most tdT+ cells are 
rounded and in circulation (Fig. 1), then only a third of tdT+ cells were AcLDL labelled (32.3% 
±8.2, n=4).  
 To reconcile the differences in our results at E8.0, E8.5 and E9.0, we next used an earlier 
marker for EMPs, Runx1 2, to test whether Runx1+ cells could also uptake AcLDL.  Yolk sacs of 
embryos at E8.5 (8-10 somite pairs) were dissociated and stained with antibodies against Runx1, 
PECAM-1 and with AcLDL. We found that 76.4 ±5.7% of PECAM-1+ endothelial cells co-stain 
with AcLDL (n=4); and that 84.4 ±4.0% of Runx1+ cells are labelled by AcLDL (n=4, Fig. 3E).  
Furthermore, 87.3 ±10.6% of  Runx1+ yolk sac cells were also PECAM-1+ (n=4, Fig. 3F). As 
such, EMPs are capable of taking up AcLDL while displaying an endothelial-like phenotype, but 
EMPs and EMP-derived cells in circulation lose this ability. 
We took advantage of selective AcLDL uptake to perform time-lapse microscopy of 
EMP extravasation. Embryos were injected with fluorescent AcLDL at 4-6 somite pairs and then 
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cultured. At E9.0, embryos were transferred to a heated microscope stage. At the start of the 
time-lapse experiment (Supplemental Movie 1), we identified a tdT+ cell that was elongated and 
integrated in the endothelium and that had been labeled with AcLDL at E8.5 (Fig. 4 snapshots, t 
= 0.7hr, white arrowhead). The cell rounded up and budded into the vessel lumen (t = 7.6 to 
9.4hr, white arrowhead). By the end of the time-lapse experiment, the cell began to divide 
(t=10.1hr, white arrowheads). A second tdT+ cell can be observed rounded at the beginning of 
the experiment (Fig. 4, t = 0.7hr, yellow arrowheads), which divides to form two daughter cells (t 
= 2.5 to 7.6hr, yellow arrowheads). One of the daughter cells enters circulation, whereas the 
other remains in the vessel wall (t = 8.3hr, yellow arrowhead). We previously observed 
endothelial cell division frequently preceding cell entry into circulation in avian embryos 38. Our 
results here clearly demonstrate that the cells that differentiate into EMPs are luminal and take 
up AcLDL before EMP commitment occurs but stop taking up AcLDL once they enter 
circulation. The results also suggest that cell division may be associated with the transition into 
circulation. 
 
Blood flow facilitates EMP emergence from the endothelium but is not required for 
differentiation 
Since we observed that EMPs first appear around the stage when circulation begins, we 
investigated whether EMP production and transition from the endothelium into circulation was 
dependent on blood flow. Previous studies using a genetic mouse model that lacks blood flow 
reported no difference in the number or morphology of EMPs at E10.0 20. We surgically ablated 
blood flow in Csf1rMeriCreMerRosa26tdT embryos, using a technique that we previously developed, 
whereby the inlet to the heart is severed and embryos are cultured overnight 39. Only viable 
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embryos with a beating heart but no circulating cells were analyzed. In agreement with previous 
reports 20, our quantification showed that arresting circulation did not alter the total number of 
tdT+ cells (Fig. 5A-B). With normal circulation, tdT+ cells were distributed equally in the 
vascular plexus, whereas in the absence of flow, EMPs were mostly confined to the blood islands 
(Supplemental Fig. 6). The majority of tdT+ cells were rounded and in circulation in control 
embryos, but in flow-ablated embryos, a greater number of tdT+ cells remained in the 
endothelium (pink arrowhead, Fig. 5C-D). Only cells in the plexus proximal to the embryo were 
analyzed. 
Nitric oxide production in response to shear stress has been found to decrease adhesion 
molecules in endothelial cells 40,41 and increase the number of HSCs released by the hemogenic 
endothelium in zebrafish and cultured embryoid bodies 31,32. We therefore tested whether nitric 
oxide affected EMP development by treating embryos with a nitric oxide donor (DETA 
NONOate), in the presence and absence of flow. Treatment with DETA NONOate did not affect 
the number of tdT+ cells (Fig. 5A-B). Flow ablation in embryos, however, had no effect on the 
transition from the endothelium into circulation when DETA NONOate was present (Fig. 5C-D). 
Collectively, this shows that blood flow facilitates the transition of EMPs from the endothelium 
into circulation, but that exogenous nitric oxide alone is sufficient to induce this process. Neither 
blood flow nor nitric oxide treatment significantly altered the total number of EMPs or EMP-
derived cells produced in the yolk sac.  
 
Early myeloid cells circulate and patrol similarly to adult monocytes 
To understand myeloid cell behavior and function during remodeling, we returned to in 
vivo time-lapse microscopy of Csf1rMeriCreMerRosa26tdT embryos. Similar to monocytes in adult 
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vasculature, we found that EMP-derived cells were able to move along embryonic vasculature 
(Supplemental Movie 2, 3). Circulating tdT+ cells can be identified by streaks of red moving at 
high speed in the vessel in these movies. A tdT+ cell is first observed perivascularly 
(Supplemental Movie 2, Fig. 6, t =0.8hr), then it enters the circulation and moves within the 
vessel at speeds much lower than other nearby circulating cells (t=1.8 to 5.7hr). Patrolling 
monocytes in the adult move along the endothelium independent of the direction of flow 42. The 
patrolling behavior of EMP-derived cells suggests that they are responsive to signaling 
molecules on the embryonic endothelium. 
 
CSF1-Fc injection increases the number of myeloid cells and disrupts venous remodeling 
The temporal emergence of yolk sac EMPs just at the onset of circulation prompted us to 
consider if early myeloid cells have a function during vascular remodeling. No vascular defects 
have been observed in CSF1R loss-of-function studies 5; therefore, we investigated the effects of 
CSF1R gain-of-function on vascular development. The cytokine macrophage colony-stimulating 
factor (M-CSF, or CSF1) can induce the survival, proliferation and differentiation of myeloid 
cells via interactions with its receptor CSF1R in vitro and in vivo 43. We injected wild-type 
embryos with CSF1-Fc cytokine or PBS at E8.5 43, cultured embryos for 24 hours, and then 
immunostained for CSF1R and CD31 (Fig. 7A). At E8.5, all CSF1R+ cells are c-kit positive and 
represent EMPs 2. Exogenous CSF1-Fc resulted in a striking increase in the number of CSF1R+ 
cells (red cells) compared to control embryos. While we observed that CSF1R+ cells are 
normally equally distributed in the venous and arterial plexus, CSF1-Fc injection caused the vast 
majority of these cells to localize to the venous plexus. Arterial and venous regions were 
identified as shown in Supplemental Figure 7. In normal vasculogenesis, the morphology of the 
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venous plexus begins as a honeycomb shape, and then remodels upon circulation to form parallel 
vessels that are connected by transverse vessels (Fig. 7B, left and Supplemental Fig. 7). When 
embryos were injected with CSF1-Fc, the honeycomb patterning was retained, indicating that 
remodeling of the venous plexus failed to occur (Fig. 7B, right). No effects were observed in 
remodeling of the arterial plexus (Fig. 7C). We quantified differences in the venous (Fig. 7D) 
and arterial remodeling (Fig. 7E) by measuring the angle of vessels relative to mean angle for the 
region (see Methods). Normal venous remodeling results in a Gaussian distribution of angles 
since the majority of vessels align parallel to one another (Fig. 7D). The distribution of vessel 
angles of CSF1-Fc injected yolk sacs was randomized, resulting in a relatively flat distribution 
(Fig. 7D). In the arterial plexus, large arteries and arterioles are separated by capillaries that do 
not align with the larger vessels. These capillary vessels are much more numerous than the large 
vessels and dominate the quantification. As such, a Gaussian distribution is not observed in 
either the control or injected embryos (Fig. 7E). We also investigated other features of vascular 
morphology, including average vessel diameter, density of branch points, average segment 
length and the density of avascular regions. These metrics revealed no differences in the arterial 
and venous plexuses between control and CSF1-Fc injected embryos (Supplemental Fig. 8).  
 
DISCUSSION 
In mammalian 2 and zebrafish embryos 1,2, myeloid cells first appear just prior to the 
onset of blood circulation and vascular remodeling , suggesting an important developmental 
function of these cells in vascular remodeling. This is the first report to show a functional role for 
EMP-derived cells in developmental vascular remodeling. While macrophages were classically 
believed to develop from progenitors in the hematopoietic blood islands 34, the recent finding 
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that EMPs express most endothelial markers and co-reside in the endothelial lining 20 have led to 
a general acceptance of an endothelial cell origin to EMPs 16,17 . Yet prior to this report, direct 
evidence for this was lacking. Our findings definitively show that EMPs arise from two non-
exclusive extra-embryonic sites: blood hematopoietic islands and endothelial cells of the yolk sac 
capillary plexus.  
While most EMPs do develop in the hematopoietic blood islands, one third of EMPs arise 
outside this region. We consistently quantified the same percentage of EMPs of non-blood island 
origin (32%), using two independent quantification techniques: immunostaining (Fig. 1I) and 
surgical removal (Fig. 2D). In concert with previous reports 17,20,21, we find that regardless of 
origin, all EMPs co-express genes typical of an endothelial cell profile, such as VE-Cadherin. 
This therefore raises the possibility that blood island-derived EMPs also arise from endothelial 
cells in that region of the yolk sac. This is supported by the fact that injection of AcLDL at 4-6 
somite pairs leads to labelling of almost all EMP-derived cells. Blood island-derived EMPs differ 
morphologically from EMPs arising outside the blood islands, displaying a rounded appearance 
even when they first differentiate at E8.5 (Supplemental Fig. 5). This may represent inherent 
cellular differences in EMPs with respect to site of origin, or represent extrinsic differences in 
the biological signals that are present in the densely-packed stationary blood islands, versus the 
sparsely populated, but dynamic and flow-exposed blood vessels in regions more proximal to the 
embryo. 
We have identified AcLDL uptake as a tool to distinguish endothelial cells from late 
EMPs. AcLDL has previously been used to stain endothelial cells during development of HSCs 
from the AGM 10. We never observed double-labeled cells when we injected 
Csf1rMeriCreMerRosa26tdT embryos with AcLDL at later stages (E9.0). We could only achieve 
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double-labeling if we injected AcLDL at E8.0 and then cultured the embryos for 24 hours. 
Because we inject the AcLDL intravascularly, we can state that the cells that differentiate into 
EMPs were in a luminal location at the time of AcLDL injection. The fact that the cells that 
differentiate into EMPs were able to take up AcLDL indicates that these cells were functionally 
endothelial cells at the time of injection. The co-expression of Runx1+ in AcLDL+ endothelial 
cells at 10 somite pairs (Fig. 3E) does, however, suggest a hemogenic potential at this stage. 
Time-lapse analysis of mouse AGM explants have shown that HSCs start budding from 
the vessel wall but never dissociate completely 11, perhaps due to the lack of blood flow in the 
explant model used. In our time-lapse movies where blood flow is ongoing, the EMPs can be 
seen rounding up from the endothelium, then suddenly disappearing from the region of interest 
within a single frame; a fast movement that can only be caused by the cell entering blood flow. 
In this same time-lapse experiment (Supplemental Movie 1), we also observed that only one of 
the two daughter cells was released into circulation. We could not extend the movie long enough 
to verify the fate of the second cell. It may have entered circulation or may have reintegrated into 
the endothelium. Asymmetric cell division, defined as one daughter cell retaining stem-like 
properties while the other differentiates, is prevalent during stem cell proliferation 44. Therefore, 
the difference in the behavior of the two daughter cells is of significant interest.  
We found that blood flow is important to stimulate the emergence of EMP-derived cells 
from the yolk sac endothelium, but does not affect the total number of EMP-derived cells in the 
vascular plexus. This is somewhat contrary to previous findings, which either show that the 
number of HSCs produced by the endothelium is increased by shear stress 31,32, or show that 
neither number nor morphology of EMPs is affected by altered blood flow patterns 20,31,32. It is 
important to note that the Frame et al. study used a different model (i.e., Ncx-/- embryos), 
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examined a later stage of development (E10.0) and did not distinguish between blood islands and 
vascular plexus-derived EMPs. Therefore, a number of reasons could explain differences in our 
results. First, we limited our analyses to the yolk sac vascular plexus more proximal to the 
embryo, since the large majority of blood island-derived EMPs had a rounded phenotype and 
would obscure any detectable differences between control and flow-ablated embryos. We believe 
that this is the principal reason for the difference between our results. Ncx-/- embryos are 
resorbed by E10.5 45, and may consequently release reactive oxygen as cells die, which could 
trigger the same events as flow-induced nitric oxide production. Thus, the differences in stage 
could also explain the discrepancy in findings. Another explanation is that differences are the 
result of an embryo culture model versus an in vivo model. Flow produces nitric oxide, and our 
results indicate that nitric oxide alone can induce the transition of EMPs into circulation. The fact 
that we can rescue the flow-abated phenotype using a nitric oxide donor suggests that the 
observed differences are not simply an artifact of embryo culture. Nitric oxide reduces cell-cell 
adhesion molecules in endothelial cells 40,41, which would facilitate the transition from the 
endothelial phenotype to the rounded phenotype.  
In order to investigate the function of early myeloid cells in vascular remodeling, we 
injected embryos with exogenous CSF1-Fc ligand, which resulted in an increase in CSF1R+ cells 
that localized primarily to the venous plexus. We did not observe a difference in the arterial-
venous identity of endothelial cells that produce EMPs at E8.5 (data not shown), as other have 
also reported 20. We also randomized injection location such that increase in venous myeloid 
cells cannot be explained by limited dispersal of CSF1-Fc. In adults, leukocytes only extravasate 
in post-capillary venules, which is thought to occur due to the lower shear forces present in 
venules 46. Thus, the venous positioning of CSF1R+ cells when stimulated with CSF1-Fc may 
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have resulted from increased adherence and/or extravasation in veins compared to arteries, rather 
than an increase in myeloid cell production by venous endothelial cells. The observed defects 
being limited to the venous plexus may have also been due to the location of CSF1R+ cells rather 
than a venous-specific activity of these cells. Other reports have previously shown that in the 
adult, ablation of CSF1 results in reduced vascular density and remodeling 28, whereas increased 
CSF1 enhances macrophage recruitment, angiogenesis and remodeling in tumor tissues 47. 
Similarly, we find that in the embryo, CSF1/CSF1R signaling must be tightly regulated during 
vascular remodeling; as exogenous CSF1-Fc disrupts venous remodeling. 
Collectively, this is the first report that conclusively delineates a functional and 
spatiotemporal relationship of yolk sac EMPs with yolk sac endothelial cells. We validate that 
EMPs can arise from the vascular endothelium in vivo in a flow-dependent, nitric oxide-induced 
mechanism, that they behave and patrol in embryonic blood vessels similar to adult monocytes, 
and lastly show that early myeloid cells are important for early vascular remodeling.  
 
 
EXPERIMENTAL PROCEDURES 
Transgenic mouse models: Rosa26CAG-LSL-tdTomato Cre-reporter males (JAX # 007909) were 
mated with either constitutive Csf1riCre (JAX # 021024) or inducible Csf1rMeriCreMer (JAX # 
019098) females. Unless otherwise stated, inducible Csf1rMeriCreMer dams were injected at E7.75 
with a single intraperitoneal dose of tamoxifen dissolved in corn oil (75mg/kg of body weight, 
Cayman Technologies, # 13258). Animal use procedures conformed to the guidelines of and 
were approved by the Ethics Committees for Animal Use of KU Leuven and McGill University 
Health Centre. 
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Antibodies: The following antibodies were used for flow cytometry and immunohistochemistry 
analysis: CD31 (BD Bioscience, #553371; DSHB, 2H8), CD34-FITC (eBiosciences, #11-0341), 
Ter119-PE (BD Biosciences, #553673), Runx1 (Abcam, ab92336), c-kit-FITC (eBiosciences, 
#11-1171), CSF1R (Abcam, #Ab32633; eBioscience AFS98), and VE-Cadherin (R&D, 
#AF1002). Alexa-Fluor tagged secondary antibodies (Invitrogen) were used for all non-
conjugated primary antibodies with the exception of anti-Armenian Hamster secondary 
(AlexaFluor647, Abcam). 
Embryo culture and manipulation: To isolate the origins of EMPs, hematopoietic blood 
islands were dissected from embryos at 3-5 somite pairs using #55 forceps. To impede blood 
flow and shear stress, the vitelline vein was severed pre-circulation (4-5 somite pairs) using #55 
forceps to prevent cardiac output flow 39,48. To mimic the release of nitric oxide induced by shear 
stress in cultured embryos, media was supplemented with 10 μM of DETA NONOate. In all 
experiments, embryos were placed in culture and allowed to develop ex vivo for 16-24 hours, as 
previously described 33. Only data from embryos with a visibly beating heart after culture were 
used for analysis. For all culture experiments with the inducible Cre model, 10 μM 4-
hydroxytamoxifen (Sigma, # H6278) was added to the culture media. 
Flow cytometry processing and analysis: Embryos were harvested and dissected at the stage 
indicated in 20% FBS in PBS. Care was taken to remove the Reichert’s membrane and 
ectoplacental cone, which have CSF1R-expressing syncytiotrophoblasts. Isolated yolk sacs were 
dissociated from the embryo proper, placed in separate tubes, then processed and analyzed as 
described 49, and according to antibody manufacturer instructions. 7-AAD or EF780 viability dye 
was used to exclude dead cells and debris. Flow cytometry was performed using FACSCanto II 
or FACS AriaIII and data analysis was performed using FACS Diva software and Flow Jo. 
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Gating controls were performed with yolk sacs that were non-stained, single stained and double-
stained, and, when appropriate, secondary antibody only stained (Supplemental Fig. 3).  
Quantification of vascular morphology: Images of the vasculature were thresholded and 
skeletonized to identify all branch points. The angle of all vessels was measured in Photoshop. 
The average angle for all vessels was subtracted from each angle measurement, then 90 degrees 
was added to normalize the orientation of each image. The distribution of angles between 
treatments was analyzed using a Kolmogorov-Smirnov test. Other vessel morphology 
characteristics were analyzed from the thresholded images using Biologic Analyzer software. 
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FIGURE LEGENDS 
 
Figure 1 – EMPs and EMP-derived cells increase with developmental stage but lose their 
endothelial cell characteristics at later stages. Csf1riCreRosa26tdT yolk sacs were harvested at 
E8.5 (10 somite pairs, A), E9.0 (15 somite pairs, B) and E9.5 (25 somite pairs, C) to visualize 
tdT+ cells. The number of total of tdT+ cells increased based on immunofluorescence of 
Csf1riCreRosa26tdT embryos (D, n=4-5 per stage) and of CSF1R+ cells based on flow cytometry 
of wild type embryos (E, n=6 at E8.5 and n=9 at E9.5). Blood vessels were counterstained with 
CD31 (F-H, green). Endothelial-like tdT+ cells (F and H, arrowheads) were blindly quantified 
based on 3 phenotypic criteria (CD31 co-expression, cell shape, and vessel integration) by 
immunofluoresence. Analysis was limited to yolk sac vessels proximal to the embryo proper. 
The number of tdT+ cells with an endothelial phenotype was initially 32% but decreased in older 
embryos (I, n=4-5 embryos per stage). The percentage of CSF1R+ cells that co-stained for VE-
Cadherin was also measured by flow cytometry and confirmed the decrease in endothelial 
staining in older embryos (J). Scale bars: 250 μm (A-C), 50 μm. (F-H) All values are mean ± 
SEM. *p < 0.05; two-tailed Student’s t-test.  
 
Figure 2 – EMPs develop from hematopoietic blood islands and the vascular plexus. 
Schematic of embryos dissected at E8.0 (3-5 somite pairs) and cultured with only the 
ectoplacental cone removed (control) or with the blood islands (BI) excised (A). Tissues above 
red dotted line were removed. Brightfield images after culture demonstrate that embryos develop 
well and that the yolk sac is inflated in both control and experimental embryos (B, n=5 for each 
condition). Fluorescent images of Csf1riCreRosa26tdT control and blood island-depleted embryos 
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show tdT+ cells (red) develop in the absence of BI but in reduced numbers (C). Flow cytometry 
analysis was used to quantify differences in the percentage of tdT+ yolk sac cells between control 
and blood island depleted embryos (D; n = 4 control, SEM = 0.8; n= 3 BI removed, SEM = 0.6, 
p =0.01). Scale bars: 500μm (B-C). Two-tailed Student’s t-test. 
 
Figure 3 - CSF1R+ EMPs are positive for several hematopoietic/endothelial cell markers 
but do not take up AcLDL. Confocal microscopy images of wild-type yolk sacs dissected at 
E9.0 (15 somite pairs) and immunostained for CSF1R and for hemogenic markers c-kit (A, n=3) 
and CD34 (B, n=3). White arrowheads indicate CSF1R+ cells that co-express 
hemogenic/hematopoietic CD34 and c-kit. Though CSF1R+ cells expressed most endothelial cell 
markers, they did not take up AcLDL as endothelial cells do (C, green). Counterstaining with 
VE-Cadherin shows AcLDL+ endothelial cells (blue). Embryos were then dissected at either 
E8.0 (4-6 somite pairs) ot E8.5 (10-12 somite pairs), injected with AF488-AcLDL and cultured 
for 24 hours.  Quantification of tdT+ AcLDL+ cells show that the majority of tdT+ cells are also 
AcLDL+ when the injection is done before EMPs arise, however only a third of tdT+ cells are 
labelled if injected after EMPs arise (D). Embryos at E8.5 (8-10 somite pairs) were dissected and 
stained for hemogenic endothelium marker Runx1, endothelial marker PECAM-1, and AF594-
AcLDL. Flow cytometry analysis shows that most Runx1+ cells at this stage are AcLDL+ (E) and 
PECAM-1 positive (F).  Scale bar: 20 μm.  
 
Figure 4 – EMPs bud from endothelium and divide prior to entering circulation. 
Csf1rMeriCreMerRosa26tdT embryos were pulsed with tamoxifen in utero at E7.75, harvested at E8.5 
and injected with Alexafluor488 acetylated low-density lipoprotein (AF488-AcLDL) to label 
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endothelial cells (green). Embryos were cultured for 16 hours in the presence of 4-
hydroxytamoxifen and then time-lapsed. Images were taken every 6 minutes on an environment-
controlled confocal microscope for 10 hours (see Supplemental Movie 1). A tdT+ cell (white 
arrowhead) appears with an endothelial phenotype in the vessel wall, then rounds and buds up 
from the endothelium. In the last few frames, this cell begins to divide (t=10.1hr, white 
arrowheads). A second tdT+ cell (yellow arrowheads) divides into two cells, and one of the 
daughter cells enters into circulation (yellow arrowheads, at approximately 7.6 hr). Scale bar: 50 
μm. 
 
Figure 5 – Blood flow facilitates the entry into circulation of endothelial-like EMPs in a 
nitric oxide-dependent manner. Csf1rMeriCreMerRosa26tdT embryos were dissected at 4-5 somite 
pairs and cultured with normal circulation (n=5), with ablated circulation (n=7), in the presence 
of DETA NONOate (n=4), and with both DETA NONOate and flow-ablation (n=4). Yolk sacs 
were counterstained for VE-Cadherin (A, green). Only cells in the plexus proximal to the embryo 
were analyzed. Quantification confirms that no significant difference in total number of tdT+ 
cells is present under any of the conditions (B). Higher magnification images show an increase in 
endothelial-like tdT+ cells in the absence of flow (C, purple arrowheads). Flow ablation increases 
the percent of endothelial-like tdT+ cells (D). In the presence of exogenous nitric oxide, no 
difference in the percentage of endothelial-like tdT+ cells is observed between control and 
ablated flow embryos. Scale bars: 50μm (A); 200μm (C). All values are mean ± SEM. *p < 0.05; 
ANOVA followed by Tukey’s multiple comparisons test. 
 
Figure 6 – EMP-derived cells circulate but also patrol along the vessel wall. 
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Csf1rMeriCreMerRosa26tdT embryos were pulsed with tamoxifen in utero at E7.75, harvested at E9.0 
and injected with Alexa Fluor488-conjugated acetylated low-density lipoprotein (AF488-
AcLDL) to label endothelial cells (green). Images were taken every 6 minutes. An EMP-derived 
cell (red) intravasates through the vessel wall (green) and enters circulation (white arrowhead). 
The cell is observed moving within the vessels at speeds much lower than surrounding 
circulating cells, which can be detected as red streaks. Panels on right hand side indicate cell 
tracking at 2.7 and 5.7 hours in yellow. Scale bar: 25μm. 
 
 
Figure 7 – Exogenous CSF1-Fc administration increases the number of early myeloid cells 
and disrupts remodeling in the venous plexus. Embryos were dissected at E8.5 (10 somite 
pairs) and injected with either PBS or CSF1-Fc and then cultured for 24 hours. CSF1-Fc 
treatment resulted in an increase in the number of CSF1R+ cells (red) localizing to the venous 
plexus (A, n=5-6 embryos). Injection of CSF1-Fc disrupted venous (B), but not arterial 
remodeling (C). Blinded quantification of vessel angles confirms that remodeling was 
significantly impaired in the venous plexus (D), but not arterial plexus (E). Scale bars: 100μm 
(A), 200μm (B-C). All values are mean ± SEM. Distributions were compared using a 
Kolmogorov-Smirnov test. 
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